



THE STATE
of **ALASKA**
GOVERNOR MIKE DUNLEAVY

Department of Health and Social Services

OFFICE OF THE COMMISSIONER

Anchorage

3601 C Street, Suite 902
Anchorage, Alaska 99503-5923
Main: 907.269.7800
Fax: 907.269.0060

Juneau

PO Box 110601
350 Main Street, Suite 404
Juneau, Alaska 99811-0601
Main: 907.465.3030
Fax: 907.465.3068

June 22, 2021

Dear Colleagues,

The FDA has modified the Emergency Use Authorizations (EUAs) for Bamlanivmab/Etesevimab and Casirivimab/Imdevimab, also known as the Lilly antibody and the Regeneron antibody, respectively.

- For both preparations allow for clinician consideration of what deems “high risk” rather than the previous ridged criteria
- Casirivimab/Imdevimab dose has changed from 1200mg/1200mg to 600mg/600mg
- Casirivimab/Imdevimab is now authorized to administer SQ as well as IV
- Both preparations have updated sections of the Provider fact sheet to include antiviral resistance with current variants of concern
- Please visit the following for complete EUA and other changes
 - Casirivimab/Imdevimab: <https://www.fda.gov/media/145611/download>
 - Bamlanivmab/Etesevimab: <https://www.fda.gov/media/145802/download>

Under the EUA, treatment is NOT authorized for patients hospitalized for COVID-19, those who require oxygen therapy due to COVID-19, or those who require an increase in their baseline oxygen flow rate due to COVID-19. Please note that an individual must be within 10 days of symptom onset and must have a documented positive COVID-19 test to be considered appropriate for therapy.

These medications are currently being distributed throughout the United States and widely available. If interested the State of Alaska Department of Health and Social Services has a supply of both preparations available for distribution. Please contact Dr. CJ Kim (cj.kim@alaska.gov) to request either product. Additional resources and information are attached regarding each medication.

With the winding down of the pandemic response many communities are standing down pop up community infusion centers. For example, the Alaska Airline center in Anchorage will be closing to monoclonal infusions after June 30, 2021. We encourage providers to consider having these therapeutics available for your patients to administer at your facility. CMS had updated CPT/HCPCS codes and increased reimburse for administration of these medications: <https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-mono-clonal-antibodies>

Thank you for all that you do in serving your community and providing great care to your patients.

Sincerely,

A handwritten signature in black ink, appearing to read "AZink".

Anne Zink, MD
Chief Medical Officer
Alaska DHSS